Freenome, Inc.

United States

Last price 12.48 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.34B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen™ CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The ...